Bronchogen

Lungs & airways Research only Animal studies Synthetic short peptide (Cytogen)

Also called AEDL peptide

A four-amino-acid Khavinson peptide associated with the lining of the bronchi. It is studied for effects on gene expression in bronchial epithelial cells, including DNA binding and promoter methylation.

Evidence at a glance

Evidence
Animal studies — Not yet studied in people
Status
Research compound only
Dosing
No human study has set a dose

Cell-culture work from the St Petersburg institute that developed it. No independent human data.

What studies report

How it works

A Khavinson short peptide: at two to four amino acids it is small enough to pass through cell and nuclear membranes intact. The proposed mechanism is that it binds specific sites on nuclear DNA and changes which genes are switched on in its target tissue, rather than acting on a surface receptor the way most peptides do.

Small enough to pass through and act on DNA in the nucleus

Where it acts

Lungs

The library groups this compound under Lungs & airways. The diagram shows that target, not every tissue it reaches.

Illustrated

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Airway and bronchial supportChronic lung conditions

Reasons people seek it out — not a list of proven effects.

Status: Research compound. Not approved.

Route
Subcutaneous injection, or oral capsule depending on the preparation
Sequence
Ala-Glu-Asp-Leu
Formula
C18H30N4O9
Molecular weight
446.5 g/mol
CAS
857267-12-0
Available as
20 mg
View on PubChem →

Search PubMed for Bronchogen → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.